Trump administration signals initial steps to deal with drug prices

The noted effort by the Trump administration would likely have a limited impact, affecting prices of older drugs whose patents and exclusivity have expired and lack competitors. In contrast, the major driver of drug spending growth in 2016 was new brands that had been on the market for less than 2 years, according to a recent research report. Gerard Anderson is quoted in this article.